Baxter (BAX) Revenue & Revenue Breakdown
Baxter Revenue Highlights
Latest Revenue (Y)
$14.81B
Latest Revenue (Q)
$3.59B
Main Segment (Y)
Pharmaceuticals
Main Geography (Y)
Non-US
Baxter Revenue by Period
Baxter Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $14.81B | -1.99% |
| 2022-12-31 | $15.11B | 18.22% |
| 2021-12-31 | $12.78B | 9.52% |
| 2020-12-31 | $11.67B | 2.74% |
| 2019-12-31 | $11.36B | 2.11% |
| 2018-12-31 | $11.13B | 5.36% |
| 2017-12-31 | $10.56B | 3.92% |
| 2016-12-31 | $10.16B | 1.96% |
| 2015-12-31 | $9.97B | -40.21% |
| 2014-12-31 | $16.67B | 9.25% |
| 2013-12-31 | $15.26B | 7.53% |
| 2012-12-31 | $14.19B | 2.14% |
| 2011-12-31 | $13.89B | 8.18% |
| 2010-12-31 | $12.84B | 2.24% |
| 2009-12-31 | $12.56B | 1.73% |
| 2008-12-31 | $12.35B | 9.63% |
| 2007-12-31 | $11.26B | 8.53% |
| 2006-12-31 | $10.38B | 5.37% |
| 2005-12-31 | $9.85B | 3.58% |
| 2004-12-31 | $9.51B | 6.65% |
| 2003-12-31 | $8.92B | 9.94% |
| 2002-12-31 | $8.11B | 5.83% |
| 2001-12-31 | $7.66B | 11.12% |
| 2000-12-31 | $6.90B | 8.09% |
| 1999-12-31 | $6.38B | -3.32% |
| 1998-12-31 | $6.60B | 7.51% |
| 1997-12-31 | $6.14B | 12.87% |
| 1996-12-31 | $5.44B | 7.73% |
| 1995-12-31 | $5.05B | -45.86% |
| 1994-12-31 | $9.32B | - |
Baxter generated $14.81B in revenue during NA 2023, up -1.99% compared to the previous quarter, and up 133.13% compared to the same period a year ago.
Baxter Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $3.59B | -7.54% |
| 2023-12-31 | $3.88B | 4.77% |
| 2023-09-30 | $3.71B | 0.03% |
| 2023-06-30 | $3.71B | 1.59% |
| 2023-03-31 | $3.65B | -6.12% |
| 2022-12-31 | $3.89B | 3.02% |
| 2022-09-30 | $3.77B | 0.72% |
| 2022-06-30 | $3.75B | 1.05% |
| 2022-03-31 | $3.71B | 5.49% |
| 2021-12-31 | $3.51B | 8.93% |
| 2021-09-30 | $3.23B | 4.13% |
| 2021-06-30 | $3.10B | 5.16% |
| 2021-03-31 | $2.95B | -7.39% |
| 2020-12-31 | $3.18B | 7.03% |
| 2020-09-30 | $2.97B | 9.35% |
| 2020-06-30 | $2.72B | -3.00% |
| 2020-03-31 | $2.80B | -7.80% |
| 2019-12-31 | $3.04B | 6.59% |
| 2019-09-30 | $2.85B | 0.39% |
| 2019-06-30 | $2.84B | 7.90% |
| 2019-03-31 | $2.63B | -7.36% |
| 2018-12-31 | $2.84B | 2.67% |
| 2018-09-30 | $2.77B | -2.64% |
| 2018-06-30 | $2.84B | 6.16% |
| 2018-03-31 | $2.68B | -3.50% |
| 2017-12-31 | $2.77B | 2.48% |
| 2017-09-30 | $2.71B | 3.92% |
| 2017-06-30 | $2.60B | 5.25% |
| 2017-03-31 | $2.48B | -6.43% |
| 2016-12-31 | $2.65B | 3.40% |
| 2016-09-30 | $2.56B | -1.04% |
| 2016-06-30 | $2.58B | 8.84% |
| 2016-03-31 | $2.38B | -8.76% |
| 2015-12-31 | $2.60B | 4.66% |
| 2015-09-30 | $2.49B | -36.12% |
| 2015-06-30 | $3.89B | 3.43% |
| 2015-03-31 | $3.76B | -15.83% |
| 2014-12-31 | $4.47B | 6.55% |
| 2014-09-30 | $4.20B | -1.57% |
| 2014-06-30 | $4.26B | 7.92% |
| 2014-03-31 | $3.95B | -9.55% |
| 2013-12-31 | $4.37B | 15.74% |
| 2013-09-30 | $3.77B | 2.86% |
| 2013-06-30 | $3.67B | 6.41% |
| 2013-03-31 | $3.45B | -8.13% |
| 2012-12-31 | $3.75B | 7.94% |
| 2012-09-30 | $3.48B | -2.66% |
| 2012-06-30 | $3.57B | 5.43% |
| 2012-03-31 | $3.39B | -5.73% |
| 2011-12-31 | $3.59B | 3.31% |
| 2011-09-30 | $3.48B | -1.61% |
| 2011-06-30 | $3.54B | 7.67% |
| 2011-03-31 | $3.28B | -6.12% |
| 2010-12-31 | $3.50B | 8.50% |
| 2010-09-30 | $3.22B | 0.94% |
| 2010-06-30 | $3.19B | 9.12% |
| 2010-03-31 | $2.93B | -15.65% |
| 2009-12-31 | $3.47B | 10.33% |
| 2009-09-30 | $3.15B | 0.70% |
| 2009-06-30 | $3.12B | 10.59% |
| 2009-03-31 | $2.82B | -9.81% |
| 2008-12-31 | $3.13B | -0.63% |
| 2008-09-30 | $3.15B | -1.19% |
| 2008-06-30 | $3.19B | 10.84% |
| 2008-03-31 | $2.88B | - |
Baxter generated $3.59B in revenue during Q1 2024, up -7.54% compared to the previous quarter, and up 92.41% compared to the same period a year ago.
Baxter Revenue Breakdown
Baxter Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 18 |
|---|---|---|---|---|
| Pharmaceuticals | $2.25B | $2.09B | - | - |
| Hillrom | - | $2.94B | $212.00M | - |
| Clinical Nutrition | - | - | - | $877.00M |
| Medication Delivery | - | - | - | $2.67B |
| Other Product Or Services | - | - | - | $510.00M |
| Advanced Surgery | - | - | - | $800.00M |
| Renal | - | - | - | $3.66B |
| Acute Theapies | - | - | - | $517.00M |
Baxter's latest annual revenue breakdown by segment (product or service), as of Dec 23: Pharmaceuticals (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | $578.00M | $1.67B | $580.00M | $540.00M | $519.00M | $537.00M | $496.00M | - | - | - | - | - | - | - | - | - | - |
| Healthcare Systems and Technologies | $265.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Medical Products And Therapies | $263.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Kidney Care | $214.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| E M E A Segment | - | - | - | $762.00M | $714.00M | $692.00M | $738.00M | $699.00M | $779.00M | $783.00M | $738.00M | - | - | - | - | - | - |
| Hillrom | - | - | - | $743.00M | $731.00M | $735.00M | $715.00M | $755.00M | - | - | - | - | - | - | - | - | - |
| E M E A | - | - | - | - | - | - | - | - | - | - | - | $744.00M | $705.00M | - | - | - | - |
| Acute Theapies | - | - | - | - | - | - | - | - | - | - | - | - | - | $137.00M | $122.00M | $129.00M | $129.00M |
| Advanced Surgery | - | - | - | - | - | - | - | - | - | - | - | - | - | $214.00M | $200.00M | $204.00M | $182.00M |
| Clinical Nutrition | - | - | - | - | - | - | - | - | - | - | - | - | - | $215.00M | $218.00M | $221.00M | - |
| Medication Delivery | - | - | - | - | - | - | - | - | - | - | - | - | - | $660.00M | $652.00M | $681.00M | $676.00M |
| Other Product Or Services | - | - | - | - | - | - | - | - | - | - | - | - | - | $122.00M | $146.00M | $139.00M | $103.00M |
| Renal | - | - | - | - | - | - | - | - | - | - | - | - | - | $953.00M | $910.00M | $931.00M | $868.00M |
| Nutrition | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $223.00M |
Baxter's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Pharmaceuticals (43.79%), Healthcare Systems and Technologies (20.08%), Medical Products And Therapies (19.92%), and Kidney Care (16.21%).
Baxter Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $7.00B | - | - | - | - |
| Non-US | $7.81B | - | - | - | - |
| EMEA | - | $3.71B | $3.55B | $3.13B | $2.97B |
| Asia Pacific | - | $2.75B | $2.80B | $2.48B | $2.30B |
| Latin America And Canada | - | $1.43B | $1.25B | $1.19B | $1.27B |
| Americas | - | - | - | $6.07B | $6.09B |
Baxter's latest annual revenue breakdown by geography, as of Dec 23: Non-US (52.74%), and UNITED STATES (47.26%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Western Europe, Canada, Japan, Australia and New Zealand | $1.16B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EMEA | $778.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Non-US | $1.93B | $5.79B | $1.94B | $42.00M | $43.00M | $47.00M | $38.00M | $33.00M | $41.00M | $401.00M | $759.00M | $747.00M | $706.00M | $739.00M | $710.00M | $666.00M | $719.00M | - | - | - |
| UNITED STATES | $1.66B | $5.16B | $1.77B | $35.00M | $38.00M | $34.00M | $38.00M | $36.00M | $37.00M | $203.00M | $222.00M | $217.00M | $216.00M | $1.29B | $216.00M | $209.00M | $204.00M | $199.00M | $1.19B | $1.12B |
| Non Us | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.65B | $1.51B |
Baxter's latest quarterly revenue breakdown by geography, as of Mar 24: Non-US (34.99%), UNITED STATES (30.03%), Western Europe, Canada, Japan, Australia and New Zealand (20.90%), and EMEA (14.08%).
Baxter Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BDX | Becton, Dickinson and | $19.37B | $4.99B |
| BAX | Baxter | $14.81B | $3.59B |
| ALC | Alcon | $10.09B | $2.46B |
| RMD | ResMed | $4.69B | $1.20B |
| HOLX | Hologic | $4.03B | $1.01B |
| COO | Cooper Companies | $3.59B | $942.60M |
| TFX | Teleflex | $2.97B | $749.69M |
| WST | West Pharmaceutical Services | $2.95B | $702.00M |
| NVST | Envista | $2.57B | $623.60M |
| ICUI | ICU Medical | $2.26B | $596.46M |
| MMSI | Merit Medical Systems | $1.26B | $338.00M |
| EMBC | Embecta | $1.12B | $272.50M |
BAX Revenue FAQ
What is Baxter’s yearly revenue?
Baxter's yearly revenue for 2023 was $14.81B, representing a decrease of -1.99% compared to 2022. The company's yearly revenue for 2022 was $15.11B, representing an increase of 18.22% compared to 2021. BAX's yearly revenue for 2021 was $12.78B, representing an increase of 9.52% compared to 2020.
What is Baxter’s quarterly revenue?
Baxter's quarterly revenue for Q1 2024 was $3.59B, a -7.54% decrease from the previous quarter (Q4 2023), and a -1.56% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $3.88B, a 4.77% increase from the previous quarter (Q3 2023), and a -0.05% decrease year-over-year (Q4 2022). BAX's quarterly revenue for Q3 2023 was $3.71B, a 0.03% increase from the previous quarter (Q2 2023), and a -1.72% decrease year-over-year (Q3 2022).
What is Baxter’s revenue growth rate?
Baxter's revenue growth rate for the last 3 years (2021-2023) was 15.87%, and for the last 5 years (2019-2023) was 30.37%.
What are Baxter’s revenue streams?
Baxter's revenue streams in c 23 are Pharmaceuticals
What is Baxter’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Baxter was Pharmaceuticals. This segment made a revenue of $2.25B, representing 100.00% of the company's total revenue.